Shanghai Henlius Biotech, Inc. (FRA:2E8)

Market Cap	3.37B +15.9%
Revenue (ttm)	811.79M +16.5%
Net Income	100.71M +0.8%
EPS	0.18 +0.0%
Shares Out	n/a
PE Ratio	33.49
Forward PE	21.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	6.15
Previous Close	6.80
Day's Range	6.15 - 6.15
52-Week Range	5.90 - 9.05
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn’s diseas...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 3,762
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2E8

Financial Performance

In 2025, Shanghai Henlius Biotech's revenue was 6.67 billion, an increase of 16.46% compared to the previous year's 5.72 billion. Earnings were 827.04 million, an increase of 0.80%.

Financial numbers in CNY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 26, 2026

Data Sources Report a data error